Journal: The Journal of Allergy and Clinical Immunology. in Practice

Article Title: A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

doi: 10.1016/j.jaip.2021.02.054

Figure Lengend Snippet: Approaches to COVID-19 vaccine evaluated included universal vaccination vs a risk-stratified approach, with primary outcomes of total hospitalizations and fatalities evaluated from a health care perspective.

Article Snippet: The Pfizer-BioNTech COVID-19 vaccine EUA was based on safety data of 37,586 participants in an ongoing multinational randomized placebo controlled trial including the United States, who were followed for a median of 2 months after the second dose of vaccine administration.

Techniques:

Journal: The Journal of Allergy and Clinical Immunology. in Practice

Article Title: A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

doi: 10.1016/j.jaip.2021.02.054

Figure Lengend Snippet: One-way sensitivity analysis of anaphylaxis risk. When risk of vaccine anaphylaxis exceeds 0.8%, risk stratification was the most cost-effective strategy (WTP = 10,000,000 per death prevented). Typical rates of vaccine anaphylaxis are estimated at 1.3 per million, with COVID-19 anaphylaxis rates estimated at 11.1 per million. , WTP , Willingness to pay.

Article Snippet: The Pfizer-BioNTech COVID-19 vaccine EUA was based on safety data of 37,586 participants in an ongoing multinational randomized placebo controlled trial including the United States, who were followed for a median of 2 months after the second dose of vaccine administration.

Techniques:

Journal: The Journal of Allergy and Clinical Immunology. in Practice

Article Title: A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

doi: 10.1016/j.jaip.2021.02.054

Figure Lengend Snippet: Two-way sensitivity analysis of anaphylaxis risk and COVID-19 risk. As risk of COVID-19 increased, cost-effectiveness of a risk-stratified approach required vaccine deferral at higher anaphylaxis risk thresholds.

Article Snippet: The Pfizer-BioNTech COVID-19 vaccine EUA was based on safety data of 37,586 participants in an ongoing multinational randomized placebo controlled trial including the United States, who were followed for a median of 2 months after the second dose of vaccine administration.

Techniques: